Ebola Vaccine Regimen demonstrated robust and durable immune response in adults and children in data published in The Lancet Infectious Diseases – Johnson & Johnson
Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo), generated robust… read more.